AU629109B2 - Tenidap as an inhibitor of the release of elastage by neutrophils - Google Patents

Tenidap as an inhibitor of the release of elastage by neutrophils Download PDF

Info

Publication number
AU629109B2
AU629109B2 AU73586/91A AU7358691A AU629109B2 AU 629109 B2 AU629109 B2 AU 629109B2 AU 73586/91 A AU73586/91 A AU 73586/91A AU 7358691 A AU7358691 A AU 7358691A AU 629109 B2 AU629109 B2 AU 629109B2
Authority
AU
Australia
Prior art keywords
tenidap
elastase
mammal
neutrophils
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU73586/91A
Other languages
English (en)
Other versions
AU7358691A (en
Inventor
Leland David Loose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU7358691A publication Critical patent/AU7358691A/en
Application granted granted Critical
Publication of AU629109B2 publication Critical patent/AU629109B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU73586/91A 1990-03-19 1991-03-18 Tenidap as an inhibitor of the release of elastage by neutrophils Ceased AU629109B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US495888 1990-03-19
US07/495,888 US5006547A (en) 1990-03-19 1990-03-19 Tenidap as an inhibitor of the release of elastase by neutrophils

Publications (2)

Publication Number Publication Date
AU7358691A AU7358691A (en) 1992-08-06
AU629109B2 true AU629109B2 (en) 1992-09-24

Family

ID=23970396

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73586/91A Ceased AU629109B2 (en) 1990-03-19 1991-03-18 Tenidap as an inhibitor of the release of elastage by neutrophils

Country Status (17)

Country Link
US (1) US5006547A (de)
EP (1) EP0448261B1 (de)
JP (1) JPH0678230B2 (de)
KR (1) KR960016511B1 (de)
AT (1) ATE133071T1 (de)
AU (1) AU629109B2 (de)
CA (1) CA2038410C (de)
DE (1) DE69116404T2 (de)
DK (1) DK0448261T3 (de)
HU (1) HU212492B (de)
IE (1) IE70732B1 (de)
IL (1) IL97520A (de)
MY (1) MY107227A (de)
NZ (1) NZ237450A (de)
PH (1) PH27229A (de)
PT (1) PT97062B (de)
ZA (1) ZA911980B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5122534A (en) * 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
EP1390062A4 (de) * 2001-05-02 2005-09-14 Blood Res Center Modulatoren der elastase-inhibitor-sekretion
CA2657606A1 (en) 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
EP2886541A1 (de) * 2013-12-19 2015-06-24 Sanofi Oxindolderivate, ihre Herstellung und ihre therapeutische Verwendung zur Behandlung von durch AMPK vermittelten Erkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4678802A (en) * 1985-07-09 1987-07-07 Pfizer Inc. 1-acylcarbamoyloxindole-3-carboxamides as antiinflammatory agents
US5036099A (en) * 1987-02-02 1991-07-30 Pfizer Inc. Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
DE3852145T2 (de) * 1987-02-18 1995-04-06 Beecham Group Plc Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US4853409A (en) * 1988-04-13 1989-08-01 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
DE3814504A1 (de) * 1988-04-29 1989-11-09 Bayer Ag (alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
PH27229A (en) 1993-05-04
KR960016511B1 (ko) 1996-12-14
EP0448261B1 (de) 1996-01-17
DE69116404D1 (de) 1996-02-29
IE910861A1 (en) 1991-09-25
PT97062B (pt) 1998-07-31
IL97520A (en) 1995-12-31
HUT60622A (en) 1992-10-28
AU7358691A (en) 1992-08-06
EP0448261A2 (de) 1991-09-25
CA2038410C (en) 1995-01-24
MY107227A (en) 1995-10-31
ATE133071T1 (de) 1996-02-15
US5006547A (en) 1991-04-09
EP0448261A3 (en) 1992-04-08
PT97062A (pt) 1991-10-31
DK0448261T3 (da) 1996-02-12
NZ237450A (en) 1997-02-24
JPH04234814A (ja) 1992-08-24
JPH0678230B2 (ja) 1994-10-05
IE70732B1 (en) 1996-12-11
HU212492B (en) 1996-07-29
IL97520A0 (en) 1992-06-21
KR910016327A (ko) 1991-11-05
HU910871D0 (en) 1991-09-30
DE69116404T2 (de) 1996-05-30
ZA911980B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
AU629109B2 (en) Tenidap as an inhibitor of the release of elastage by neutrophils
EP0337628B1 (de) 3-Substituierte 2-Oxindol-1-carboxamid-Derivate zur Hemmung der Aktivität der T-Zellen
AU637745B2 (en) Use of tenidap to inhibit the activity of myeloperoxidase
AU601325B2 (en) 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
AU630580B2 (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
EP0543855A1 (de) Verwendung von arylhydroxyharnstoffverbindungen zur behandlung von atherosklerose
CORREIA et al. Severe acute form of adult dermatomyositis treated with cyclosporine
US5192790A (en) 3-substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
JP2690768B2 (ja) 肝線維化抑制剤
US4287196A (en) Method of inhibiting prolactin secretion
Miyamoto et al. The effects of R-75,317 on antiglomerular basement membrane glomerulonephritis in rats
MANDAL et al. BLOOD CHOLINESTERASE ACTIVITY IN ALBlNO RATS FOLLOWING HIGH DOSES OF TETRACYCLINE, CHLORAMPHENICOL AND TRIMETHOPRIM
FR2649320A1 (fr) Nouvelle association medicamenteuse

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired